Privacy Policy
Treatment Action Group believes strongly in protecting the privacy and integrity of all personal information of our donors, website visitors, and email recipients. This privacy policy explains the information practices we use with regard to: How we use your information How we protect your information How to unsubscribe from mailing lists How to correct information…2023 Pre-CROI Community HIV Cure Research Workshop
Webinars • 2023The 2023 Pre-CROI Community HIV Cure Research Workshop will be held on Saturday, February 18th in the Sequoia Glacier Room at Crowne Plaza Hotel, 1113 - 6th Avenue, Seattle, WA 98101.
2022 Pipeline Report
Pipeline • 2022Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
Breaking Barriers: Surveying Community Perspectives of COVID-19 Vaccine Research
Publication • 2021This report aims to raise the profile of discussions that have been taking place regarding community understanding and involvement in COVID-19 vaccine research. It presents the results of an online survey developed by TAG, along with the Black AIDS Institute and the COVID-19 Prevention Trials Network in the fall of 2020 seeking community perspectives on COVID-19 vaccine development.
Time for $5 Coalition Statement: Cepheid’s Updated GeneXpert Pricing Does Not Address Country Needs
Statement / Press • 2021The Time for $5 Coalition, comprised of over 150 civil society organizations globally, calls out Cepheid for the company’s insufficient and self-serving GeneXpert pricing packages for low- and middle-income countries (LMICs), announced May 6, 2021.
PrEPared? Long-Acting PrEP Access in Communities Marginalized by the U.S. Healthcare System
TAGline • 2021By Abraham Johnson The announcement that HIV Prevention Trials Network (HPTN) had two successful studies on long-acting technologies (LAT) to prevent HIV — HPTN 083 and 084 — came with much excitement. Populations most impacted by HIV could possibly have an even greater opportunity to prevent HIV. LATs provide for potentially easier adherence, fewer side…
Launch of Public Health Partnership to Tackle the Silent Epidemic of Hepatitis C in Low- and Middle-Income Countries
Statement / Press • 2021The Drugs for Neglected Diseases initiative (DNDi), Médecins Sans Frontières (MSF), FIND, the global alliance for diagnostics, and the Treatment Action Group are joining forces to tackle a ‘silent’ public health injustice: the continuing disparities in access to diagnostics and treatment for the hepatitis C virus (HCV) in low- and middle-income countries (LMICs), home to 75% of those living with this viral illness.
Good COPs or Bad COPs: Promoting Interventions for Coinfections and AIDS in 2020 PEPFAR Country Operational Plans (COPs)
Webinars • 2020On January 22, 2020, Treatment Action Group (TAG), Médecins Sans Frontières (MSF) Access Campaign, Health GAP, IMPAACT4TB, and AVAC presented this webinar on how to engage in PEPFAR COPs advocacy. Materials are online now.
Treatment Action Group and AVAC Statement on Pfizer/BioNTech COVID-19 Vaccine Efficacy Announcement
Statement / Press • 2020Treatment Action Group (TAG) and AVAC welcome today’s announcement that preliminary data from the efficacy trial of Pfizer/BioNTech’s mRNA COVID-19 vaccine indicates a high level of protection against COVID-19. Our organizations urge caution, however, given the very limited information that is available only through a company press release.
Statement on Human Challenge Studies for COVID-19 Vaccine Development
Statement / Press • 2020Two recent developments have brought renewed publicity to proposals to conduct human challenge studies to test COVID-19 vaccine candidates: an open letter from the organization 1DaySooner and media reports that Adrian Hill’s Oxford University research group is planning a challenge study, taking advantage of the lack of regulatory oversight of human challenge experiments in the United Kingdom.